Initial Combination Therapy with Ambrisentan and Tadalafil in PAH (AMBITION)
AI-Generated Summary
Educational summary — always verify with primary sourceSequential add-on therapy was standard in PAH. AMBITION tested whether upfront combination therapy (ERA + PDE5i) was superior to monotherapy.
Multicenter RCT (n=500) comparing upfront ambrisentan + tadalafil vs. ambrisentan alone or tadalafil alone in treatment-naive PAH patients.
Combination therapy reduced the risk of clinical failure events by 50% vs. pooled monotherapy (HR 0.50, p<0.001). Combination therapy also improved 6MWD, NT-proBNP, and WHO functional class.
Upfront combination therapy (ERA + PDE5i) is now standard of care for newly diagnosed PAH. Ambrisentan + tadalafil is the best-studied combination. This trial changed PAH management from sequential to upfront combination therapy.
Open-label design. Pooled monotherapy comparator. Predominantly low-to-intermediate risk patients.
This is THE trial that changed PAH management. Upfront dual combination = standard of care. Know the 50% risk reduction in clinical failure events.
Access the complete publication on PubMed